CA2268265A1 - Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences - Google Patents

Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences Download PDF

Info

Publication number
CA2268265A1
CA2268265A1 CA002268265A CA2268265A CA2268265A1 CA 2268265 A1 CA2268265 A1 CA 2268265A1 CA 002268265 A CA002268265 A CA 002268265A CA 2268265 A CA2268265 A CA 2268265A CA 2268265 A1 CA2268265 A1 CA 2268265A1
Authority
CA
Canada
Prior art keywords
cells
gene
recombinant
recombination
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002268265A
Other languages
English (en)
Inventor
Willem P. C. Stemmer
Helmuth H. G. Van Es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgene BV
Maxygen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2268265A1 publication Critical patent/CA2268265A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés de mise au point d'acides nucléiques destinés à être utilisés dans une thérapie génique grâce à une recombinaison récursive de séquences. Beaucoup de ces procédés mettent au point des vecteurs, aussi bien viraux que non viraux, afin de présenter des propriétés perfectionnées. Par exemple, des vecteurs sont mis au point pour présenter des propriétés perfectionnées de titres viraux, d'infectivité, d'expression d'un gène dans un vecteur, de spécificité de tissu, de capacité de génome viral, de rétention épisomique, de manque d'immunogénicité des vecteurs ou d'un produit d'expression de ces vecteurs, d'intégration spécifique du milieu, de stabilité accrue, ou de capacité à conférer une résistance cellulaire à une infection d'un micro-organisme. L'invention concerne également un enzyme isolé O<6>-méthylguanine-ADN méthyltransférase (MGMT).
CA002268265A 1996-09-27 1997-09-26 Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences Abandoned CA2268265A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3774296P 1996-09-27 1996-09-27
US60/037,742 1996-09-27
PCT/US1997/017302 WO1998013485A1 (fr) 1996-09-27 1997-09-26 Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences

Publications (1)

Publication Number Publication Date
CA2268265A1 true CA2268265A1 (fr) 1998-04-02

Family

ID=21896054

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268265A Abandoned CA2268265A1 (fr) 1996-09-27 1997-09-26 Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences

Country Status (4)

Country Link
EP (1) EP0963434A4 (fr)
AU (1) AU4597197A (fr)
CA (1) CA2268265A1 (fr)
WO (1) WO1998013485A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
DK1717322T3 (da) 1997-01-17 2012-10-22 Codexis Mayflower Holdings Llc Udvikling af hele celler og organismer ved rekursiv sekvensrekombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1999021979A1 (fr) 1997-10-28 1999-05-06 Maxygen, Inc. Vecteurs du papillomavirus humain
EP1030861A4 (fr) 1997-10-31 2001-09-05 Maxygen Inc Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
BR9910174A (pt) 1998-05-01 2001-03-06 Maxygen Inc Processo para se obter um gene recombinante otimizado de resistência à praga, biblioteca, e, processo para se obter um organismo que seja patogênico a uma praga de vegetal
EP1090024A2 (fr) 1998-06-17 2001-04-11 Maxygen, Inc. Technique de production de polynucleotides aux caracteristiques souhaitees
AU5347999A (en) 1998-08-12 2000-03-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
US6951719B1 (en) * 1999-08-11 2005-10-04 Proteus S.A. Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained
JP2002537758A (ja) * 1998-09-29 2002-11-12 マキシジェン， インコーポレイテッド コドン変更された遺伝子のシャッフリング
JP2002526107A (ja) 1998-10-07 2002-08-20 マキシジェン， インコーポレイテッド マイコトキシンの解毒のための核酸を生成するためのｄｎａシャッフリング
EP1129184A1 (fr) 1998-11-10 2001-09-05 Maxygen, Inc. Adp-glucose pyrophosphorylase modifiee pour l'amelioration et l'optimisation de phenotypes vegetaux
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
EP1198565A1 (fr) * 1999-07-07 2002-04-24 Maxygen Aps Methode de production de polypeptides modifies
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001059071A2 (fr) 2000-02-09 2001-08-16 Genvec, Inc. Methodes de preparation et d'utilisation d'une bibliotheque de vecteurs viraux
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
EP1297146A2 (fr) 2000-06-23 2003-04-02 Maxygen, Inc. Nouveaux promoteurs chimeres
EP1360290A2 (fr) 2000-06-23 2003-11-12 Maxygen, Inc. Molecules costimulatrices
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US20040219525A1 (en) 2000-08-25 2004-11-04 Heiko Haertel Plant polynucleotides encoding novel prenyl proteases
ES2366830T3 (es) 2003-08-25 2011-10-25 Funzyme Biotechnologies Sa Nuevas proteínas fúngicas y ácidos nucelicos que codifican las mismas.
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination

Also Published As

Publication number Publication date
AU4597197A (en) 1998-04-17
WO1998013485A1 (fr) 1998-04-02
EP0963434A1 (fr) 1999-12-15
EP0963434A4 (fr) 2000-10-25

Similar Documents

Publication Publication Date Title
CA2268265A1 (fr) Procedes permettant l&#39;optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences
CA2266423A1 (fr) Procedes permettant l&#39;optimisation d&#39;une therapie genique grace a un rearrangement et une selection recursifs de sequences
US20210139872A1 (en) Crispr having or associated with destabilization domains
US20240093193A1 (en) Dead guides for crispr transcription factors
JP3681752B2 (ja) 遺伝子治療に使用できる宿主 − ベクタ系
Thomas et al. Progress and problems with the use of viral vectors for gene therapy
US6297004B1 (en) Recombinant viruses displaying a nonviral polypeptide on their external surface
KR20160056869A (ko) 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160019553A (ko) 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
KR20160030187A (ko) 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
EP3230451A1 (fr) Arn guides protégés (pgrnas)
AU2016278990A1 (en) Novel CRISPR enzymes and systems
KR20150105956A (ko) 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
CA2932479A1 (fr) Relargage, utilisation et applications therapeutiques de systemes crispr-cas et compositions pour maladies et troubles viraux et attribuables au vhb
KR20160089526A (ko) 입자 전달 성분을 이용한 표적 장애 및 질병에 대한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 이용 및 치료 적용
JPH11196880A (ja) 変異型ｌｏｘＰ配列とその応用
WO1996021007A2 (fr) Systemes de transfert genique a mediation par bacteriophage capables d&#39;effectuer une transfection des cellules eucaryotiques
Van Tendeloo et al. Gene therapy: principles and applications to hematopoietic cells
FR2737501A1 (fr) Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
Balicki et al. Gene therapy of human disease
Boulikas Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications
EP1002120A1 (fr) Vecteurs adenoviraux chimeres
WO2001059071A2 (fr) Methodes de preparation et d&#39;utilisation d&#39;une bibliotheque de vecteurs viraux
JP4159620B2 (ja) 組換えアデノウイルスの製造方法
van Winkel CRAd with capsid incorporated mesothelin for higher anti-tumor immunization

Legal Events

Date Code Title Description
FZDE Discontinued